Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.
暂无分享,去创建一个
D. Galetta | A. Addeo | G. Banna | F. Roila | P. Economopoulou | A. Collazo-Lorduy | P. Kosmidis | G. Mountzios | H. Linardou | M. Garassino | G. Lo Russo | A. Calles | A. De Toma | A. Gili | G. Metro | A. Christopoulou | D. Signorelli | P. Baxevanos | A. Camerini | B. Jiménez | M. Banini | Juliana Rey Cobo